X
Shock as FDA rejects Mesoblast’s Ryoncil in paediatric graft versus host disease
https://pharmaphorum.com/news/fda-issues-shock-rejection-for-mesoblasts-ryoncil-in-graft-versus-host-disease/
graft versus host disease
Janssen/AbbVie drug approved in graft-versus-host disease
First use for Imbruvica outside blood cancer.
Imbruvica granted fourth Breakthrough status
The drug is also granted Orphan Drug Designation by the FDA.